Pfizer sad its Tafamidis phase 3 transthyretin cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months
Protagonist Therapeutics said it is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).
Ablynx’s lupus erythematosus treatment vobarilizumab has failed to meet primary endpoint in the phase II dose-ranging study.
Mitsubishi Tanabe Pharma has partnered with Hitachi to improve the efficiency of clinical trials for the development of new drugs through the latter's artificial intelligence (AI) technology.
Roche has announced that its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) showed a clinically significant survival benefit in a phase III lung cancer study.
GSK has commenced a phase III trial to evaluate Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE).
Arena Pharmaceuticals has reported positive topline phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC).
Heron Therapeutics’ pain drug HTX-011 has succeeded in two phase 3 trials in patients undergoing bunionectomy and hernia repair by meeting all their primary and key secondary points.
The US Food and Drug Administration (FDA) has placed a clinical hold on Solid Biosciences' IGNITE DMD phase Phase I/II trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD).
AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.